<DOC>
	<DOC>NCT00044135</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and effectiveness of 12 weeks of treatment with clevudine, at one of three doses, in patients chronically infected with hepatitis B virus.</brief_summary>
	<brief_title>A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<criteria>HBV DNA positive with DNA levels at screening greater than or equal to 3,000,000 copies/mL. Documented to be HBsAg positive for &gt; 6 months OR HBsAg positive and IgM antiHBc negative and antiHBs negative. Patients may be HBeAg positive, and antiHBe negative OR HBeAg negative (precore mutant) and antiHBe positive. HBeAg positive and antiHBe negative OR HBeAg negative (precore mutant) and antiHBe positive with positive HBsAg for the previous 6 months AST and ALT levels which are less than or equal to 10 times the upper limit of normal. Bilirubin levels less than or equal to 1.5 x ULN or bilirubin levels &gt; 1.5 x ULN with diagnosis of Gilbertâ€™s disease and conjugated bilirubin within normal limits. Currently receiving antiviral, immunomodulatory or corticosteroid therapy Previous treatment with lamivudine, lobucavir, adefovir, famciclovir, or any other investigational nucleoside for HBV infection Previous treatment with interferon must have ended at least 6 months prior to screening visit History of ascites, variceal hemorrhage or hepatic encephalopathy Coinfection with HCV or HIV Evidence of cirrhosis or hepatocellular carcinoma (alpha fetoprotein)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2002</verification_date>
	<keyword>clevudine</keyword>
	<keyword>hepatitis B</keyword>
</DOC>